Skip to Main Content


COVID-19 Webinar Briefing for Healthcare Industry: March 23

Webinar Only

Monday, March 23
12:00 – 1:00 p.m. MDT

To help our clients respond to rapidly changing legal issues surrounding the coronavirus update, Holland & Hart will hold a weekly COVID-19 Legal Briefing beginning Monday, March 23, at noon Mountain Time. Members of our healthcare and labor and employment teams will be on hand to address the latest news and updates affecting healthcare providers.

To join the March 23 live webinar, click here.
Event password: 1234

If you have a question you’d like to submit for the presenters, please send those to Laura Squyres. In addition to providing the latest updates, we will answer as many questions as we can during the webinar. For those we are unable to respond to during the webinar, we will answer those offline.

We also encourage you to visit Holland & Hart’s Coronavirus Resource Site. The Healthcare specific section is under the “Protecting Your Business” tab. We’re regularly updating the Resource Site with fresh content as the COVID-19 outbreak itself and the legal and regulatory responses continue to evolve. We welcome you to subscribe via the Resource Site homepage to receive alerts from Holland & Hart’s Coronavirus Task Force.

In the meantime, here is a recent update we’d like to share:

DEA Says Health Care Professionals Can Prescribe Controlled Substances During Coronavirus Emergency
mHealth Intelligence (3/18, Heath) reports the DEA announced that health care professionals can prescribe controlled substances, including opioids, via telemedicine during the current coronavirus public health emergency. The DEA’s Diversion Control Division said in a statement, “For as long as the Secretary’s designation of a public health emergency remains in effect, DEA-registered practitioners may issue prescriptions for controlled substances to patients for whom they have not conducted an in-person medical evaluation, provided all of the following conditions are met.” Click here for the DEA’s Diversion Drug Control Division's COVID-19 Information Page.

Questions about the webinar? Contact Laura Squyres.


Unless you are a current client of Holland & Hart LLP, please do not send any confidential information by email. If you are not a current client and send an email to an individual at Holland & Hart LLP, you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us, unless we have already agreed to represent you or we later agree to do so. Thus, we may represent a party adverse to you, even if the information you submit to us could be used against you in a matter, and even if you submitted it in a good faith effort to retain us.